NCT02039726: A trial that was reported late by Daiichi Sankyo
This trial has reported, although it was 215 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02039726 |
|---|---|
| Title | A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 31, 2014 |
| Completion date | Feb. 22, 2018 |
| Required reporting date | Feb. 22, 2019, midnight |
| Actual reporting date | Sept. 25, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 215 |